Dataset opportunity
Genesisaec — 监管记录数据集机会
Genesisaec 持有的中等监管记录数据集，可用于监管 RAG 和合规性 Copilots。
Score
73.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
63%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球监管事务市场规模在 2025 年估值为 173.7 亿美元，预计在 2026 年至 2035 年期间的复合年增长率为 8.55%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — 许可权待明确
Buyer persona
RegTech 和合规性 AI 供应商
Genesisaec 的 监管记录数据集 是一个全面的 文本 模态文件集合，包括 cGMP 合规记录、制药设施设计和其他 监管 文件。这个结构化的 知识库，包含广泛的 业务记录 和 工业数据，经过专门策划，用于支持 监管 RAG 系统，从而实现针对医疗保健领域复杂合规和运营问题的先进 AI 驱动查询。
该数据的价值体现在全球 监管信息管理 市场，该市场在 2025 年的估值为 173.7 亿美元，预计将以 8.55% 的复合年增长率 增长。[8] 虽然由于敏感的客户数据（Pfizer、J&J）和专有的内部模型（如 PharmaWater Pro）需要协商才能访问，但该数据集的稀有性以及包含专有的聚合基准使其具有极高的 价值。这在一个快速增长、高风险的市场中提供了独特的竞争优势。⚠ 尽职调查（有价值的数据，可协商访问）：数据包括敏感的制药客户设施设计和 cGMP 合规记录；专有的建模平台（PharmaWater Pro）内部用于服务，不单独销售；特定设施数据的归属权可能属于客户（Pfizer、J&J），但聚合基准是专有的。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Genesisaec 拥有专有数据集，详细说明了制药设施的 FDA 和 欧盟合规 设计和运营流程。这种高稀有度的文本数据对于寻求构建先进 监管 RAG 系统的 RegTech 和合规性 AI 供应商来说是关键资产。在全球监管事务市场预计将超过 170 亿美元的情况下，该数据集为训练模型处理真实世界的 审计、CAPA/FMEA 偏差 和 调试 文档提供了独特的真相来源。
See dimension details ↓- Dataset Specificity90
主导的“监管”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume64
5 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
173.7 亿美元的监管事务市场中 8.55% 的强劲复合年增长率表明，买家对用于构建监管 RAG 等先进 AI 解决方案的专业数据有强劲且不断增长的需求。[8]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility28
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength86
5 种证据类型，5 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License36
所有权=混合，许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Genesis AEC 是一个理想的目标，其核心业务是生命科学设施的建筑和工程，这会产生有价值的专有运营、模拟和自动化数据，而它似乎并未出售这些数据。问题：来源机会中提到的“监管记录数据集”未找到；实际机会是其核心 AEC 业务的运营数据。
- Deep Qualification90
⚠ 需要审查 — Genesis AEC 是一家为生命科学客户提供建筑、工程和验证服务的公司。它生成的监管数据是其客户（例如 Pfizer、Bayer）拥有的雇佣产品，因此无法转售给第三方。[数据归其客户所有]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Knowledge base / docs
这些证据表明存在一个全面的知识库，详细说明了制药设施的整个项目生命周期，为分析设计和施工决策的 AI 模型提供了宝贵的背景数据。
Industrial data
这表明拥有专有的时间序列数据，来自制药水和能源系统的工程模型，这是 AI 供应商构建可持续性和运营效率预测模型的关键资源。
Regulatory records
这证实了存在高价值文本记录，记录了审计、纠正措施（CAPA/FMEA）和调试流程，直接证明了符合FDA和欧盟法规，可用于 AI 训练。
IoT / sensor data
这表明持有者从建筑性能的能源和液压模拟中生成预测性时间序列数据，这是训练 AI 以优化设施设计和降低运营成本的宝贵资产。
business_records
这些证据显示了结构化的业务记录，将设备清单与设施平面图和公用事业需求联系起来，为训练模型进行资产管理和空间规划提供了一个清晰、有组织的数据库。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Genesisaec Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global Regulatory Affairs Market size was valued at US$ 17.37 billion in 2025, projected to grow at a CAGR of 8.55% between 2026 and 2035 (source: Precedence Research). [8]. Investment score 73.9/100 (confidence 0.63). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Abax — 可通过 API 访问的数据集机会
View opportunity →出行Ghy — 法规记录数据集机会
View opportunity →出行Clearit — 监管记录数据集机会
View opportunity →